Safety of infliximab: primum non nocere. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients.
Parsi
Mansour A
MA
Center for Inflammatory Bowel Disease, Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation, USA.
Lashner
Bret A
BA